MyoRx

MyoRx is a biotechnology company dedicated to the development of novel therapeutics for muscle regeneration and the treatment of debilitating muscle-wasting diseases. The company’s primary focus is on addressing conditions such as sarcopenia, cancer-induced cachexia, and various muscular dystrophies by leveraging a proprietary protein engineering platform. This platform specializes in the targeted delivery and stabilization of growth factors, such as Insulin-like Growth Factor 1 (IGF-1), through advanced polymer-protein conjugation techniques. Led by experienced industry executives and scientific pioneers, MyoRx aims to fill a significant therapeutic gap in musculoskeletal health and regenerative medicine. The company is currently operating in the pre-clinical stage with programs designed to preserve and restore lean muscle mass.